This study was the first experiment that confirmed the prominent role of IDO1 in mediating EVs' therapeutic efficacy in vivo using a mouse model of experimental autoimmune encephalomyelitis (EAE)39. Here, IDO1 is linked to experimental autoimmune encephalomyelitis.